We show here a specific myeloid cell differentiation and anti-tumor activity of E7046 by antagonism of EP4 signaling and a highly potent anti-tumor activity of the novel E7046 and E7777 combination in preclinical cancer models by synergistic inhibition of both myeloid and Treg–induced TME immunosuppression. The gene discussed is PTGER4; the disease is neoplasm.